Get the app!
Back to Trades
Other4

LIGAND PHARMACEUTICALS INC

LGND

Total Value
$282.8K

Company Information

Ticker Symbol
LGND
CIK
0000886163

Insider Information

Role
Director
Director
Location
JUPITER, FL

Filing Details

Filing Date
Dec 8, 2025
Transaction Date
Dec 8, 2025
Accession Number
0002001011-25-000122
Form Type
4

Non-Derivative Transactions

DateSecuritySharesPriceTypeValue
Dec 8, 2025Common Stock2,034$69.51Exercise$141.4K

Derivative Transactions

DateSecuritySharesExercise PriceTypeValue
Dec 8, 2025Derivative2,034$69.51Exercise$141.4K

Footnotes

  1. (F1)All securities disclosed in this Form 4 are owned by certain funds managed by JALAA Equities, LP, JLV Investments, LP and affiliates (the "Funds"). Jason Aryeh is the General Partner of JALAA Equities, LP and a partner of JLV Investments, LP. By reason of the provisions of Rule 16a-1 under the Securities Exchange Act of 1934, as amended, JALAA Equities, LP, JLV Investments, LP and affiliates and Mr. Aryeh may be deemed to be the beneficial owners of the securities beneficially owned by the Funds.
  2. (F2)This Option was previously reported as a Grant of 2,329 shares, which vested in full on May 23, 2016, at an exercise price of $119.3000 per share but was adjusted pursuant to the OmniAb Inc. separation from the issuer.

SEC Filing

View on SEC Daily

View the complete filing document on SEC Daily.